Acumen Pharmaceuticals (ABOS) EPS (Weighted Average and Diluted) (2021 - 2026)
Acumen Pharmaceuticals recorded quarterly EPS (Weighted Average and Diluted) of -$0.33 in Q1 2026, up 19.51% quarter-over-quarter from -$0.41 in Q4 2025, and up 31.25% year-over-year from -$0.25 in Q1 2025.
Acumen Pharmaceuticals' EPS (Weighted Average and Diluted) history runs 6 years deep, the most recent figure standing at -$0.33 for Q1 2026.
- In Q1 2026, EPS (Weighted Average and Diluted) rose 31.25% year-over-year to -$0.33; the TTM figure through Mar 2026 stood at -$1.86 (up 4.12% YoY), while the FY2025 annual figure was -$2.0, down 16.96% from the prior year.
- EPS (Weighted Average and Diluted) came in at -$0.33 for Q1 2026 at Acumen Pharmaceuticals, up from -$0.41 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.23 in Q1 2022 to a low of -$0.68 in Q2 2025.
- A 5-year average of -$0.36 and a median of -$0.32 in 2022 frame the typical range for EPS (Weighted Average and Diluted).
- On a YoY basis, EPS (Weighted Average and Diluted) climbed as much as 99.82% in 2022 and fell as far as 160.0% in 2022.
- Acumen Pharmaceuticals' EPS (Weighted Average and Diluted) stood at -$0.32 in 2022, then increased by 9.38% to -$0.29 in 2023, then slumped by 113.79% to -$0.62 in 2024, then jumped by 33.87% to -$0.41 in 2025, then increased by 19.51% to -$0.33 in 2026.
- According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods registered -$0.33, -$0.41, and -$0.44 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1.51 |
| 10 | Acumen Pharmaceuticals | 164.37 Mn | 35.97 Mn | - | -0.33 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.33 |
| Dec 31, 2025 | -0.41 |
| Sep 30, 2025 | -0.44 |
| Jun 30, 2025 | -0.68 |
| Mar 31, 2025 | -0.48 |
| Dec 31, 2024 | -0.62 |
| Sep 30, 2024 | -0.50 |
| Jun 30, 2024 | -0.34 |
| Mar 31, 2024 | -0.25 |
| Dec 31, 2023 | -0.29 |
| Sep 30, 2023 | -0.24 |
| Jun 30, 2023 | -0.28 |
| Mar 31, 2023 | -0.28 |
| Dec 31, 2022 | -0.32 |
| Sep 30, 2022 | -0.26 |
| Jun 30, 2022 | -0.25 |
| Mar 31, 2022 | -0.23 |
| Dec 31, 2021 | 1.98 |
| Sep 30, 2021 | -0.10 |
| Jun 30, 2021 | -141.93 |